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Parvovirus B19 infection is a significant cause
of fetal death. The aim of this study was to
investigate the role ofmaternal immune status in
modulating susceptibility to fetal B19 infection.
Peripheral blood was obtained from pregnant
women (n¼ 199) with no clinical evidence of
recent B19 infection. Evaluation of ex vivo T cell
responses from 149/199 individuals showed
significantly higher interferon-g levels for sero-
positive individuals following VP1 (26836
versus 103 19 pg/ml; P¼0.003) and VP2 (242
42 versus 91 16 pg/ml; P¼0.01) antigen stimu-
lation. Significantly higher levels of interleukin-2
were also observed in seropositive individuals
following both VP1 (P¼ 0.0003) and VP2 (P¼
0.0005) stimulation. The observed Th1 cellular
response is lower than that documented pre-
viously fornon-pregnant individualsandstrongly
suggests that diminution of the maternal anti-
viral immune response may increase suscept-
ibility to fetal B19 infection. J. Med. Virol.
70:475–480, 2003.  2003 Wiley-Liss, Inc.
KEY WORDS: pregnancy; cellular immunity;
erythrovirus; interferon-g
INTRODUCTION
Human parvovirus B19 infection can cause serious
complications in the immunocompromised host includ-
ing pregnant women and individuals with underlying
blood disorders such as sickle cell disease [Woolf et al.,
1989; Serjeant et al., 1993; Heegaard and Hornsleth,
1995; Tarantino and Shahidi, 1995]. Exposure to, and
infection with, parvovirus B19 during pregnancy can
lead to fetal loss by either spontaneous abortion or non-
immune fetal hydrops occurring in 8–10% of infections
[Brown, 1989; Jordan, 1996; Kinney et al., 1988]. B19 is
transmitted across the placenta during maternal infec-
tion and subsequent fetal infection can lead to severe
anaemia. A vertical transmission rate of 33–51% has
been reported [PHLS, 1990; Yaegashi, 2000]. B19
infection during pregnancy often goes undetected as
many pregnant women are asymptomatic while other
individuals experience symptoms such as exanthema
and arthralgia [Komischke et al., 1997].
Fetal loss as a consequence of intrauterine B19
infection is highest in, but not restricted to, the first
20 weeks of gestation [PHLS, 1990]. This susceptibility
could be attributed, at least in part, to the predilection of
B19 for rapidly dividing erythroid progenitor cells. In
the second trimester, the fetal red cell mass increases
three- to fourfold and the effects of B19 may be further
compounded by the reduced life span of fetal red blood
cells. The relative immaturity of the fetal immune
response at this stage may also be a contributory factor.
Cases of late second and third trimester non-hydropic
fetal loss, caused by an acute B19 infection, have only
been reported recently [Skjo¨ldebrand-Sparre et al.,
2000; Tolfvenstam et al., 2001]. In the present study,
following an examination of incidences of intra-uterine
fetal death it was found that 7.5% (7/93) of third tri-
mester and 15% (7/47) of late second and third trimester
cases contained B19 DNA in the placental tissue. These
cases were not associated with hydrops and no other
explanations for fetal death were evident. Unusually,
none of the pregnant women showed clinical symptoms
of B19 infection and many had delayed or absent
humoral responses.
Specific anti-viral antibody is considered the major
mechanism of immune protection [Kurtzman et al.,
1989; Schwarz et al., 1990], however, more recently the
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cellular response to parvovirus B19 infection has been
explored. B19 specific T-cell proliferative responses of
recently infected and healthy individuals to the capsid
antigens [von Poblotzki et al., 1996; Corcoran et al.,
2000; Franssila et al., 2001] and to the non-structural
protein, NS1 [von Poblotzki et al., 1996; Mitchell et al.,
2001] have been observed. T helper cells secrete cyto-
kines, which have an important role in determining the
outcome of a pregnancy [Chaouat et al., 1990; Hill, 1991;
Tangri and Raghupathy, 1993]. Th1 and Th2 cells are
the major subsets of fully differentiated CD4þ T cells
and normal pregnancy is dominated by T helper cells
that secrete a Th2 type pattern of cytokines including
interleukin-4 (IL-4) and interleukin-5 (IL-5) [Wegmann
et al., 1993]. Th1 cytokines, including interferon-gamma
(IFN-g) and interleukin 2 (IL-2), are associated with a
poor pregnancy outcome and are suppressed by placen-
tal products such as progesterone, prostaglandin E2 and
cytokines such as IL-4 and IL-10 [Wegmann et al., 1993;
Kelly and Critchley, 1997]. During pregnancy, elimina-
tion of a viral infection via a Th1 response may result in
endangering the developing conceptus. Cytokines typi-
cal of a Th1 response, including IFN-g, IL-2, IL-6, and
IL-1b have been reported upon stimulation of T cells of
healthy adults with parvovirus B19 [Wagner et al.,
1995; Moffatt et al., 1996; Corcoran et al., 2000; Jordan
et al., 2001]. Furthermore, Corcoran et al. [2000] have
demonstrated that PBMCs isolated from normal healthy
individuals (n¼7, comprising 3 females) produced
IFN-g levels of 610348 pg/ml and 1765 825 pg/ml
when stimulated with VP1 and VP2, respectively.
In this study, we investigated if pregnancy, and the
associated suppression of Th1-type responses, could
modulate ex vivo B19-specific cytokine production from
T cells isolated from pregnant women to elucidate the




Heparinised blood specimens (n¼ 199) were obtained
from pregnant women with no evidence of recent par-
vovirus B19 exposure or symptoms (trimester 1 (n¼78),
trimester 2 (n¼80) and trimester 3 (n¼41)). The age
range of the volunteers was 15–50 and the mean age was
28 years. The gestation period varied from 4 to 42 weeks.
No further clinical data was available on the volun-
teers. Ethical permission for this study was obtained
from the National Maternity Hospital, Dublin, Ireland
and written consent was obtained from all volunteers
prior to specimen collection.
Antigen Expression and Purification
Parvovirus B19 recombinant VP1 and VP2 capsids
and NS1 were expressed in the baculovirus expression
system using Spodoptera frugipera cells [Brown et al.,
1990; Brown et al., 1991; Ennis et al., 2001]. Capsid and
NS1 purification have been described previously [Kerr
et al., 1999; Ennis et al., 2001].
Parvovirus B19 IgG Enzyme Immunoassays
Plasma specimens were analysed for B19 IgG specific
for the capsid antigens VP1 and VP2 in both their native
(N) and denatured (D) conformations as previously
described [Corcoran et al., 2000]. An enzyme immu-
noassay was used to measure the level of reactivity
against B19 NS1. Results are expressed as index values
(I.V.) representing specimen absorbance divided by
cut-off absorbance. The cut-off was established as the
absorbance þ2 SD greater than the mean absorbance
obtained from a panel of B19 negative samples. An IV of
<1.0 was considered seronegative. B19 IgG reactivity to
conformationally intact VP1 (VP1-N) was determined
by a commercial qualitative immunofluorescent assay
(IFA). The degree of fluorescence was graded on a scale
of 0-4 according to manufacturers’ instructions (Biotrin,
Dublin, Ireland).
T cell proliferation assays. Isolated peripheral blood
mononuclear cells (PBMCs) were cultured in triplicate
with purified recombinant VP1 (10 mg/ml), VP2 (10 mg/
ml) and NS1 (10 mg/ml) for 72 hr. Cells cultured with
medium alone or with phytohaemagglutinin (PHA: 2 mg/
ml) served as negative and positive controls, respec-
tively. The level of B19-specific T cell proliferation was
measured depending on the amount of [3H]-thymidine
incorporation during the final 4 hr of culture [Corcoran
et al., 2000].
Cytokine enzyme immunoassays. Supernatants were
removed from PBMCs cultures, at optimal timepoints,
to determine the concentration of IL-2 (24 hr) and IFN-g,
IL-4 and IL-5 concentrations (72 hr). Levels of cytokine
secreted were determined by EIA using commercially
available antibody pairs (PharMingen, San Diego,
California, USA). Concentrations were determined by
comparing the absorbance at 405 nm for test samples
with a standard curve for recombinant cytokines of
known concentration. Levels of IL-2 are expressed in
terms of index values (specimen IL-2 (U/ml) divided
by the mean negative control IL-2 level (U/ml) plus 2
standard deviations) to compensate for differences in
control IL-2 levels between experiments.
Statistical Methods
Cytokine secretion data from different treatment
groups were compared by use of Student’s t-test.
RESULTS
Seroreactivity of Study Population
Parvovirus B19 seroprevalence in the adult popula-
tion has been reported to be 60–70%. In this study,
where B19 seropositivity was defined by the presence
of antibody against VP2-N (capsid VP2), all trimester
groups had expected levels of reactivity against VP2-N
(63–71%) (Table I), thus giving a representative sample
population in terms of past B19 infection for each of the
trimesters. Levels of reactivity against VP1 ranged from
59–68% (Table I). The low level of antibody reactivity
observed against linear epitopes of VP1 (35–52%) and
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VP2 (3–15%), in the seropositive group, is indicative of
past infection of healthy individuals and also empha-
sises the importance of using capsid-based detection
systems for accurate diagnosis of past exposure to B19 in
pregnant women. It is known that antibodies against
linear epitopes on VP2 are undetectable 6 months post-
infection [So¨derlund et al., 1995]. As specimens from
this cohort exhibited the expected low level of reactivity
against linear VP2 (Table I), it can be concluded that
92% of seropositive pregnant women in this study did
not have an acute B19 infection.
Strong IFN-g Responses Dominate
the Cytokine Profile
Not all PBMCs isolated from whole blood specimens
taken from pregnant women exhibited reactivity when
stimulated with positive control (PHA) in the T cell
proliferation assay. Thus, subsequent data evaluation
involved the study of T cell responses from the 147/199
individuals with PHA-induced responses. Higher levels
of the inflammatory cytokine IFN-g were secreted by
PBMCs obtained from seropositive individuals (n¼99)
than in those obtained from seronegative donors
(n¼48). Most significant were levels of IFN-g (268
36 pg/ml) when T cells were stimulated with the immu-
nodominant capsid protein, VP1 (P¼ 0.003). Levels of
IFN-g were also significant when cells were stimulated
with the capsid protein VP2 (P¼0.01) and to a lesser
extent with NS1 (P¼ 0.09) (Table II).
In order to determine if there was a trimester-
dependent pattern in the ex vivo cytokine response,
specimens were re-classified based upon the stage of
gestation. IFN-g was detected in specimens obtained
across all three trimesters, however no significant
difference was observed in the amounts of IFN-g
secreted ex vivo, in response to all B19 antigens tested,
across the trimesters of pregnancy (Fig. 1).
B19-Specific IL-2 Production
by Pregnant Women
Although significantly high levels of IL-2 were pro-
duced by PBMCs when stimulated with B19 antigens,
initially there was no statistically significant difference
between levels produced by seropositive (n¼99) and
seronegative (n¼ 48) specimens due to the fact that
three seronegative specimens produced high levels of
IL-2 upon stimulation. Exclusion of these three speci-
mens (see Discussion) results in the observed levels
of IL-2 secretion being significantly higher in sero-
positive specimens for both VP1 (P¼ 0.0003) and VP2
(P¼ 0.0005) stimulation. Strong IL-2 production was
observed following ex vivo stimulation of PBMCs from
seropositive pregnant women (n¼99) with VP1, VP2
and NS1, resulting in IL-2 index values of 1.430.9,
1.36 0.7 and 1.27 0.9, respectively (Fig. 2). In com-
parison, IL-2 index values of 0.850.25, 0.890.25 and
0.83 0.29 were evident following analysis of T cells
from seronegative individuals when stimulated with
VP1, VP2 and NS1 (Fig. 2). In fact, 44/99 seropositive
samples produced significantly higher levels of IL-2
compared to seronegative samples (P¼0.004 for VP1,
P¼ 0.003 for VP2) despite the inclusion of the 3 serone-
gative/high IL-2 specimens in the analysis (see above).
Mean values of IL-2 for these 44 samples were
0.407 0.049 U/ml for VP1 and 0.3060.029 U/ml for
VP2. No difference was observed in the extent of ex vivo
IL-2 secretion from stimulated PBMCs between trime-
sters. Despite the bias towards Th2 cytokine production
TABLE I. Antibody Response in Plasma Obtained From












VP1-N 59 65 68
VP2-N 63 65 71
VP1-D 52 51 35
VP2-D 15 6 3
NS1-D 2 4 0
*In conformationally intact (N) and denatured (D) forms, and to the B19
nonstructural protein, NS1. B19 seropositivity was defined by the
presence of antibody against VP2-N (capsid VP2).
TABLE II. Ex Vivo IFN-g Secretion by PBMCs Isolated From
Seropositive and Seronegative Pregnant Women After






Positive (n¼ 99) 268 36 242 42 185 34
Negative (n¼ 48) 103 19 91 16 100 17
IFN, interferon; PBMCs, peripheral blood mononuclear cells.
Fig. 1. Trimester dependence of ex vivo interferon-g production
following PBMCs stimulation with B19 antigens. Isolated PBMCs were
individually stimulated with purified B19 antigens, VP1, VP2 and NS1
or either medium alone or PHA as a negative or positive control,
respectively. Seronegative (SN) and seropositive (SP) specimens were
categorised according to trimester 1 (SP (n¼ 39); SN (n¼ 20)), 2 (SP
(n¼ 41); SN (n¼17)) and 3 (SP (n¼ 19); SN (n¼ 11)). Results represent
the mean concentration of interferon-g produced from triplicate wells
(SE).
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during pregnancy, PBMC stimulation with B19 anti-
gens did not produce any significant levels of inter-
leukin-4 and -5 (data not shown).
DISCUSSION
This study represents the first simultaneous evalua-
tion of both humoral and cellular immunity against
parvovirus B19 in pregnant women. The population
cohort exhibited the expected high level of seropositivity
(63–71%) against B19 and a significant ex vivo Th-1
response against B19 antigens, though reduced com-
pared to non-pregnant individuals. Furthermore, evi-
dence is presented for the presence of a cellular response
to past B19 infection in the absence of a detectable
humoral response, which has implications for current
B19 diagnostic practices.
Overall the level of parvovirus B19 seroprevalence
amongst pregnant women in Ireland was 66% (132/199).
This evaluation compares favourably with that reported
previously in both German and US (73.2%) populations
using identical test methodology [Searle et al., 1997; US
Food and Drug Administration, 1999]. Significantly, a
lower level of IgG antibody positivity is observed against
both linearised B19 VP1 and VP2, confirming the neces-
sity for B19 IgG detection systems to utilise native B19
antigens to facilitate optimal test sensitivity [Kerr et al.,
1999]. So¨derlund et al. [1995] have shown previously
that antibodies against linear epitopes are lost within
6 months following B19 infection, thus the low level of
antibody positivity against these epitopes, observed in
the present study, confirms further that the majority of
seropositive individuals were infected at least 6 months
prior to specimen donation.
Cases of maternal infection and subsequent fetal
death due to B19 infection have been reported in all
three trimesters [Wright et al., 1996; Yaegashi et al.,
1998; Skjo¨ldebrand-Sparre et al., 2000]. Although the
direct pathogenic effects of B19 on fetal development are
a major cause of mortality, the role of the maternal
immune status in either protecting against or mediating
parvovirus B19–induced fetal loss is unknown. It is
generally accepted that a successful pregnancy requires
a Th2 response and that strong Th1 responses are
associated with pregnancy rejection [Raghupathy, 1997;
Raghupathy, 2001]. Interestingly, recent work by Luppi
et al. [2002] presents evidence of an increase in CD8þ
lymphocyte frequency in peripheral blood specimens
taken during the third trimester of pregnancy compared
to a control group. In this present study we show that ex
vivo stimulation with B19 antigens results in significant
IL-2 and IFN-g production from PBMC despite the
proposed Th2 bias of pregnancy. Comparative informa-
tion on ex vivo cytokine secretion in response to
B19 antigen stimulation is limited. However, in the
present study, the level of ex vivo IFN-g secretion was
reduced substantially from that of normal healthy in-
dividuals stimulated with the same antigens [Corcoran
et al., 2000] where B19 seropositive adults produced
IFN-g levels of 610 348 pg/ml and 1765825 pg/ml
when stimulated with VP1 and VP2, respectively.
Interferon-g production by PBMCs from pregnant
women (present study) was 205 27 pg/ml with VP1
and 17626 pg/ml with VP2 stimulation. This is sug-
gestive of a pregnancy-associated diminution of Th1
mediated immunity. In fact, a transient down-regula-
tion in the Th1 response is seen during pregnancy in
rheumatoid arthritis patients and this reduction is
associated with a state of remission as pro-inflammatory
cytokines cause the pathological damage of joints
evident during rheumatoid arthritis [Russell et al.,
1997].
The decrease in the cellular immune response to
B19 observed may be relevant to the adverse outcomes
associated with B19 infection during pregnancy. We
propose that this diminished Th1 response may
decrease the rate of B19 clearance, thus giving the virus
the opportunity to exhibit greater infectivity. A similar
phenomemon has been reported withLeishmaniamajor
parasitic infections of genetically resistant pregnant
mice whereby cellular responses against L. major were
weakened due to reduced IFN-g production during
pregnancy and was associated with diminished clear-
ance of the parasite [Krishnan et al., 1996]. In addition,
L. major infection in these mice caused an increase in
the frequency of fetal resorptions. Although a systemic
Th1 response was beneficial in fighting infection, it was
also detrimental to gestation, even at a decreased level.
IL-2 is not present normally in substantial levels
during pregnancy around the trophoblast [King et al.,
1995], however, in the present study, ex vivo stimulation
with B19 antigens elicited production of this pro-
inflammatory cytokine. IL-2 production has been ob-
served previously in women who were infected with
B19 during pregnancy [Jordan et al., 2001]. Using
immunohistochemical techniques on placental tissue
sections (n¼25), IL-2 was detected at the maternal-fetal
interface of all women in the study who seroconverted
during pregnancy despite the outcome of the pregnancy.
However, it was proposed that in pregnancies with a
poor outcome IL-2 is detectable on the fetal side of the
interface, whereas those with a positive outcome tend to
Fig. 2. Ex vivo IL-2 production following stimulation of isolated
PBMC, from seropositive (black bars) and seronegative (white bars)
individuals, with parvovirus B19 VP1, VP2 and NS1 antigens,
respectively. IL-2 results are expressed as index values (I.V.S.E.M.)
representing the amount of IL-2 produced above the background level
for each individual (I.V.¼mean IL-2 concentration (U/ml)/mean IL-2
concentration of the negative control þ2 standard deviations).
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have the IL-2 on the maternal side. It is well established
that some cytokines have adverse effects on the outcome
of pregnancy, particularly IFN-g, IL-2 and TNF-a. These
cytokines activate cytotoxic cells such as natural killer
(NK) and lymphokine activated killer (LAK) cells which
can kill trophoblast cells [Drake and Head, 1989] and
when these cytokines are administered to mice they
cause abortions [Kinsky et al., 1990]. In pregnant
women with a history of recurrent spontaneous abor-
tions significantly higher levels of NK cells [Kwak et al.,
1995], IFN-g and IL-2 expression [Tangri and Raghu-
pathy, 1993] have been found when compared to normal
pregnant women. IFN-g production by B19-specific
T cells may also be detrimental to the conceptus by
inhibiting granulocyte-macrophage colony-stimulating
factor (GM-CSF), which is involved in trophoblast
growth and differentiation [Robertson et al., 1994].
Although Th1 cytokines are important during implan-
tation and parturition of pregnant women [Haimovici
and Anderson, 1993; Aboagye-Mathiesen et al., 1996],
there may be times during pregnancy when the fetus
is more sensitive to the level of pro-inflammatory cyto-
kines. Our study shows that the levels of Th1 cytokines
did not significantly differ over the three trimesters but
the level of IFN-g produced was highest in trimester 1.
Previous studies have shown that pro-inflammatory
cytokines such as IFN-g can have deleterious effects on
the fetus during pregnancy [Raghupathy, 1997]. This
observation, combined with the relative immaturity of
the fetus during trimester 1, suggests that an increased
Th1 response to B19 may be detrimental to the fetus.
Other factors to be considered when determining the
effect of cytokines caused by B19 infection during preg-
nancy are the gestationalperiod of the infection, thestage
of differentiation of the conceptus, the level of soluble
cytokine receptors and the ratio of Th2 cytokines.
Interestingly, three of the seronegative donors pro-
duced high levels of IL-2 upon ex vivo B19 antigen
stimulation. The reason for this is unclear but recent
evidence suggests that certain individuals with past B19
infection may possess an antigen-specific cell mediated
immune response in the absence of a humoral response
to the virus. Tolfvenstam et al. [2001] observed four B19
antibody negative cases that had specific T cell memory
proven by either ELISpot assay or tetramer binding.
These observations have significant consequences for
the design of an efficacious vaccine for parvovirus B19 in
that future subunit vaccines should contain both B19
T cell and B cell epitopes.
Previous studies on B19 infection during pregnancy
have focussed on both the direct effects of B19 on the
fetus and the maternal humoral response as the major
mechanism of protection against B19-induced fetal
death. Our results, which show a significant diminu-
tion in ex vivo interferon-g secretion in response to B19
antigen stimulation, demonstrate that cellular immu-
nity against B19 is attenuated during pregnancy which
may have an adverse effect on anti-viral Th1-type
responses thereby increasing fetal susceptibility to
infection.
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